The Rundown Novo Nordisk's Wegovy Gets U.S. Approval for Liver Disease, Sam Altman Warns of AI Bubble
35 snips
Aug 18, 2025 Discover the latest stock market trends and the high stakes of Jerome Powell's upcoming address. Dive into the buzz around Novo Nordisk's Wegovy gaining U.S. approval for liver disease and its implications for the pharma market. Explore competition with Eli Lilly and the rise of GLP-1 drugs in treatment. Plus, catch up on recent financial highlights, including the impact of a celebrity wedding on local economies and Tesla's strategic lease discounts amid shifting sales.
AI Snips
Chapters
Transcript
Episode notes
Altman Says AI Could Be A Bubble
- Sam Altman warned that AI might be in a bubble even while calling AI the most important thing in a long time.
- He compared the current AI hype to the dot-com bubble and noted frothy private valuations despite limited profitability.
Massive AI CapEx Bet
- Big tech is spending heavily on AI infrastructure, with estimates of $364 billion in AI CapEx this year.
- Those investments may or may not pay off, but markets currently reward the spending trend.
Wegovy Cleared For Liver Disease
- Novo Nordisk's Wegovy got FDA approval for MASH, opening a new market beyond weight loss and diabetes.
- The approval lifted Novo Nordisk shares but competition from Eli Lilly and pricing remain key constraints.